Sarepta Therapeutics,, Inc. Common Stock (SRPT) — Analysis Summary
Sarepta Therapeutics,, Inc. Common Stock (SRPT) has a market cap of $1.99B with year-over-year revenue growth of +4.3%. Net margin stands at -38.3%. The stock trades at a P/E ratio of 30.5.
Key Takeaways
- Revenue changed +4.3% year-over-year
- Net margin of -38.3%
- P/E ratio of 30.5
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, SRPT posted revenue growth of +4.3% and trades at a P/E of 30.5.
Sarepta Therapeutics,, Inc. Common Stock (SRPT)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Debt/EBITDA at 200.8x — highly leveraged, potential refinancing risk
Interest coverage at -0.7x — earnings do not cover interest payments
Negative gross margin (-1.8%) — selling below cost
Revenue declined 15.1% vs the prior period.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
835
Headquarters
CAMBRIDGE, MA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.